What is your preferred second line therapy for an HCC patient who progressed after first line checkpoint inhibitor monotherapy?   

Would you try atezolizumab/bevacizumab or switch to a TKI?



Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Rutgers Robert Wood Johnson Medical School
This is how I was leaning - a trial of the doublet...
Sign in or Register to read more